Verana Health launches real-world dataset for uveitic macular edema
Click Here to Manage Email Alerts
Key takeaways:
- The Qdata uveitic macular edema module includes data from more than 152,000 patients.
- The dataset includes information on visual acuity, central subfield thickness and IOP.
Verana Health launched a real-world dataset for patients with uveitic macular edema, according to a press release.
The Qdata uveitic macular edema (UME) module contains information on more than 152,000 de-identified patients with an average of about 4 years of follow-up, including variables such as visual acuity, central subfield thickness and IOP.
Image: Adobe Stock
The goal of the dataset is to aid in clinical development, health economics and outcomes research, as well as other efforts to address uveitic macular edema.
“Key variables such as visual acuity, central subfield thickness and intraocular pressure are traditionally left out of many datasets because they can only be found in unstructured electronic health record data but play an important role in better understanding disease trends, therapy effectiveness and patient outcomes,” Verana Health CEO Sujay Jadhav told Healio. “The Qdata UME module addresses a crucial gap in research and treatment by incorporating EHR data sourced through Verana Health’s exclusive partnership with the American Academy of Ophthalmology IRIS Registry (Intelligent Research in Sight). With nearly 4 years of follow-up data on more than 152,000 de-identified UME patients, this high-quality data module provides a comprehensive view of real-world outcomes, enabling ophthalmologists to monitor therapy effectiveness and optimize patient management.”
Verena previously developed a Qdata module for dry eye disease and launched a module for thyroid eye disease.
Collapse
Read more about
Click Here to Manage Email Alerts